ANGIODYNAMICS INC
ANGONasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $292.5M | $303.9M | $338.8M | $316.2M | $291.0M | $264.2M |
| Operating income | −$40.0M | −$192.4M | −$51.2M | −$28.5M | −$35.3M | −$167.1M |
| Net income | −$34.0M | −$184.3M | −$52.4M | −$26.5M | −$31.5M | −$166.8M |
| Total assets | $280.1M | $317.7M | $532.6M | $552.8M | $561.4M | $594.2M |
| Total liabilities | $97.2M | $112.1M | $154.3M | $128.3M | $122.0M | $139.3M |
| Equity | $183.0M | $205.6M | $378.3M | $424.5M | $439.5M | $454.9M |
| EPS (diluted) | $-0.83 | $-4.59 | $-1.33 | $-0.68 | $-0.82 | $-4.39 |
| Shares out. | 40.6M | 40.3M | 39.7M | 39.0M | 38.4M | 37.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −13.7%
- Net margin
- −11.6%
- Return on equity
- −18.6%
- Return on assets
- −12.1%
- Return on capital (ROCE)
- −19.6%
- Liabilities / assets
- 34.7%
- Debt / equity
- 0.53×
- Book value / share
- $4.50
- Revenue growth (YoY)
- −3.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.82distress
- Accruals / assets
- −8.5%clean
- Beneish M-Score
- -2.92normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Oct 10, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-04A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
- Phase 4Recruitingreadout ~2029-02Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.0M | 7.0 | -5.7% |
| Apr 30, 2026 | 2.1M | 5.9 | -4.2% |
| Apr 15, 2026 | 2.2M | 3.3 | +18.6% |
| Mar 31, 2026 | 1.8M | 4.3 | +2.1% |
| Mar 13, 2026 | 1.8M | 6.3 | -18.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventApr 23, 2026
- Results of operations · Regulation FD disclosureApr 2, 2026
- Director / officer changeFeb 3, 2026
- Regulation FD disclosureJan 14, 2026
- Results of operations · Regulation FD disclosureJan 6, 2026
- Shareholder voteNov 12, 2025
- Results of operations · Regulation FD disclosureOct 2, 2025
- Results of operations · Regulation FD disclosureJul 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- 8-KApr 23, 2026
- 10-QApr 2, 2026
- 8-KApr 2, 2026
- SCHEDULE 13G/AMar 26, 2026
- SCHEDULE 13G/AFeb 13, 2026
- SCHEDULE 13GFeb 10, 2026
- SCHEDULE 13GFeb 9, 2026
- 8-KFeb 3, 2026
- 8-KJan 14, 2026
- SCHEDULE 13G/AJan 8, 2026
- 10-QJan 6, 2026
- 8-KJan 6, 2026
- SCHEDULE 13G/ANov 14, 2025
- 8-KNov 12, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.